It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more, CLICK HERE.
